OptimizeRx financials
$8.36+7.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.5M | $19.8M | $32.2M | $26.1M | $29.2M | $21.9M | $32.3M | $21.3M | $18.8M | $19.7M | $28.4M | $16.3M |
| Gross profit | $15.7M | $14.9M | $24.1M | $17.5M | $18.6M | $13.3M | $22.0M | $13.4M | $11.7M | $12.2M | $17.8M | $9.8M |
| Gross margin | 76.5% | 75.2% | 74.8% | 67.2% | 63.8% | 60.9% | 68.1% | 63.1% | 62.2% | 62.0% | 62.9% | 60.0% |
| Operating income | -$88.0K | $396.0K | $8.6M | $2.0M | $3.2M | -$2.1M | $3.6M | -$8.6M | -$3.7M | -$5.0M | -$8.8M | -$3.6M |
| Net income | -$703.0K | -$495.0K | $5.0M | $779.0K | $1.5M | -$2.2M | -$78.0K | -$9.1M | -$4.0M | -$6.9M | -$4.1M | -$2.9M |
| Net margin | −3.4% | −2.5% | 15.6% | 3.0% | 5.2% | −10.0% | −0.2% | −42.8% | −21.3% | −35.0% | −14.6% | −17.5% |
| Diluted EPS | $-0.04 | $-0.03 | $0.26 | $0.04 | $0.08 | $-0.12 | $0.00 | $-0.50 | $-0.22 | $-0.38 | $-0.23 | $-0.17 |
| EBITDA | $976.0K | $1.5M | $10.0M | $3.1M | $4.3M | -$1.0M | $4.7M | $22.0K | -$2.7M | -$4.0M | -$1.0M | -$3.1M |
| Operating cash flow | $8.6M | -$467.0K | $7.1M | $3.2M | $4.6M | $3.9M | $198.0K | $1.8M | $782.0K | $2.1M | -$6.3M | $1.5M |
| Free cash flow | $8.6M | -$488.0K | $7.1M | $3.2M | $4.6M | $3.8M | $181.0K | $1.8M | $737.0K | $2.1M | -$6.3M | $1.4M |
| Diluted shares | 18.8M | 18.8M | 19.0M | 19.5M | 19.0M | 18.5M | 18.4M | 18.3M | 18.3M | 18.2M | 17.8M | 16.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.1M | $20.2M | $23.4M | $19.5M | $16.6M | $16.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $19.0M | $23.3M | $25.7M | $28.1M | $28.4M | $32.5M |
| Total assets | $164.3M | $167.3M | $176.9M | $170.3M | $169.3M | $167.8M |
| Total liabilities | $33.2M | $37.7M | $48.6M | $48.1M | $50.0M | $51.5M |
| Shareholders' equity | $131.1M | $129.6M | $128.3M | $122.3M | $119.3M | $116.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology